clinical trial · NCT05363800
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.·phase1·active not recruiting·n = 74
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaHRS-3738
brief summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
started
Jun 17, 2022
primary completion
Dec 30, 2026
completion
Dec 30, 2026
last updated
Jun 5, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol